Dataset Information

Expression of FGD3 gene as prognostic factor in young breast cancer patients.

ABSTRACT: The FGD3 gene works as a cell migration inhibitor and seems to be a promising indicator of outcome in some human cancers including breast. In this study, we analysed for the first time the prognostic role of FGD3 in young breast cancer patients. We studied the relationship between traditional prognostic factors, FGD3 expression and outcome in ?40 years breast cancer patients. We found that lower FGD3 expression decreased the probability of disease-free survival (p?=?0.042) and overall survival (p?=?0.007). In a multivariate analysis for overall survival AJCC stage (p?=?0.005) and FGD3 expression (p?=?0.03) resulted independent prognostic factors. Low FGD3 expression increased the risk of death from disease (HR 5.73, p?=?0.03). Moreover, low FGD3 expression was associated with more widespread lymph node involvement (p?=?0.04) and a lower FGD3 staining intensity was found in positive-lymph-node patients vs negative (p?=?0.003) and in patients with ?10 involved lymph nodes vs <10 (p?=?0.05). Our results suggest FGD3 to be a significant independent prognostic factor in young breast cancer patients in terms of disease-free survival and overall survival. A lower expression increased the risk of recurrence and death from disease and was associated with widespread lymph node metastases.

SUBMITTER: Renda I

PROVIDER: S-EPMC6811624 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Expression of FGD3 gene as prognostic factor in young breast cancer patients.

Renda Irene I Bianchi Simonetta S Vezzosi Vania V Nori Jacopo J Vanzi Ermanno E Tavella Ketty K Susini Tommaso T

Scientific reports 20191023 1

The FGD3 gene works as a cell migration inhibitor and seems to be a promising indicator of outcome in some human cancers including breast. In this study, we analysed for the first time the prognostic role of FGD3 in young breast cancer patients. We studied the relationship between traditional prognostic factors, FGD3 expression and outcome in ≤40 years breast cancer patients. We found that lower FGD3 expression decreased the probability of disease-free survival (p = 0.042) and overall survival ( ...[more]

PMID: 31645624

Similar Datasets

Project description:Background: We obtained 2 types of clones which were termed SC (sphere-shaped clone) and NSC (non-sphere-shaped clone) from 4T1 cells by monoclonal culture. SC and NSC were distinct in morphology, surface marker, metabolism and proliferation rate. With the transcriptome sequencing data analysis, we found TMED2 expressed higher in SCs. TMED2 was a member of the transmembrane emp24 domain and might play roles in cancer cell proliferation. However, its prognostic roles in breast cancer remained unknown. We aimed to investigate the prognostic values of TMED2 in patients with breast cancer. Methods: We used UALCAN (http://ualcan.path.uab.edu) and the Human Protein Atlas (www.proteinatlas.org) to explore the TMED2 expression level and DNA methylation data between breast cancer and normal breast tissue. With Oncomine (www.oncomine.org), we investigated the copy number of TMED2 in breast cancer sample and normal breast tissue. We used the Kaplan-Meier Plotter database (http://kmplot.com/analysis) to analyze prognostic values of TMED2 mRNA expression in all breast cancers and in different intrinsic subtypes. Moreover, protein expression levels of TMED2 were confirmed by Western blot in breast cancer tissues and normal mammary tissue as well as SCs and NSCs. Results: TMED2 significantly upregulated in breast cancer patients compared to normal mammary samples. Meanwhile, the increased expression of TMED2 mRNA was closely associated with reduced overall survival (OS) in all breast cancers, and with reduced OS in patients with ER-positive, Luminal A or Luminal B breast cancer subtypes. Moreover, western blot confirmed that TMED2 increased expressed was correlated with the reduced OS at protein levels. Conclusion: Increased expression of TMED2 was significantly related to unfavorable outcomes in patients with breast cancer. Thus, we supposed TMED2 is oncogenic and a potential target for breast cancer therapy and these preliminary findings require further study to determine whether TMED2-targeting reagents might be developed for clinical application in breast cancer.

Dataset Information

Expression of FGD3 gene as prognostic factor in young breast cancer patients.

Publications

Expression of FGD3 gene as prognostic factor in young breast cancer patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets